Private equity is an alternate mode of private financing, which is composed of funds and investors that directly invest in private companies, What is Private Equity (PE)?or that engage in buyouts of public companies, resulting in the delisting of public equity. These companies are not listed or traded on any stock exchanges.
Bain Capital's Kotecha highlighted that the strongest indicator of PE's value is the long-term track record and measurable impact on portfolio companies
Investment leaders from Bain Capital, Samara Capital, BlackSoil Capital, and Multiples Alternate Asset Management speak about capital flow, business and startup growth at the BS BFSI Insight Summit
APAC private capital fundraising hits five-year low: Preqin report
The decline in overall investments happened despite the number of deals being 26 per cent higher during the same period at 283 transactions
Gaja Capital and Lok Capital have made the commitment, which will be utilised for fuelling the company's pan-India plans and also for a Rs 267-crore acquisition of Capital India Home Loans
The sharp fall in transaction value can be attributed to the absence of large-scale deals, said the Grant Thornton report
The PE inflows stood at $ 6.7 billion in 2019, $ 6.6 billion in 2020, $ 3.4 billion in 2021, $ 3.4 billion in 2022, and $ 3.9 billion in 2023
The majority of deals are priced at discounts of between 20 per cent to 25per cent of their net asset values, making them attractive for secondary buyers, said Amit Gupta, founding partner at TPG NewQ
Acquire 46.85% for Rs 846 cr; deal triggers open offer
The PE major has invested over $8 billion in the country through more than 30 deals, making it a force to reckon with. It has said it would invest around $5 billion this year in India
Country is leader in Asia Pacific for private debt, says investment data company
In its report released on Wednesday, real estate consultant Knight Frank India said the Private Equity (PE) investments in India's flexible office space sector have fluctuated significantly
Eris Lifesciences Ltd is a listed Indian pharmaceutical company and a leading player in the domestic branded formulations market
The amount of funds invested is 30 per cent higher than the July-December 2023 period, the report by industry lobby grouping IVCA and consultancy firm EY said
The New York-based investment firm's results underscore how a long spell of high interest rates has dragged down some aspects of its business while buoying others
Majority of the deal making activity involving India targeted the High Technology sector which totaled $5.8 billion, a 13.2% increase in value from the comparative period last year.
The quarterly data indicates that commercial office assets maintained their leading position, capturing approximately 51% of the total investment volume
PE investments jump by a whopping 154 per cent sequentially in April-June quarter
Special rights will now be cancelled at the time of listing instead of at the time of filing offer document
Continues to be the largest shareholder